https://www.aigom.it/wp-content/uploads/2024/11/LOC-26.11.png1227960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-26 07:14:382024-11-26 07:14:38NODAL BURDEN AND ONCOLOGIC OUTCOMES IN PATIENTS WITH RESIDUAL ISOLATED TUMOR CELLS AFTER NEOADJUVANT CHEMOTHERAPY (ypN0i+): THE OPBC-05/ICARO STUDY
https://www.aigom.it/wp-content/uploads/2024/11/LOC-19.11.png1227960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-18 17:42:362024-11-18 17:42:36UGT1A1*28 POLYMORPHISM AND THE RISK OF TOXICITY AND DISEASE PROGRESSION IN PATIENTS WITH BREAST CANCER RECEIVING SACITUZUMAB GOVITECAN.
https://www.aigom.it/wp-content/uploads/2024/11/LOC.12.11.png1134960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-10 14:16:252024-11-10 14:16:25CHARACTERISTICS AND CLINICAL OUTCOMES OF BREAST CANCER IN YOUNG BRCA CARRIERS ACCORDING TO TUMOR HISTOLOGY
https://www.aigom.it/wp-content/uploads/2024/11/loc.15gennaio.png805567Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-09 09:30:282024-11-09 09:30:2815 GENNAIO 2024, VERONA AIGOM-GIST AVANZATI: IL VALORE DELLA GESTIONE MULTIDISCIPLINARE DEL PAZIENTE
https://www.aigom.it/wp-content/uploads/2022/12/logo-sito.png00Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-09 09:03:472024-11-09 09:08:09PRESENTAZIONI 28 OTTOBRE
https://www.aigom.it/wp-content/uploads/2024/11/ART.5-11.png1238950Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-05 04:31:132024-11-05 04:31:13NEOADJUVANT CHEMOTHERAPY WITH OXALIPLATIN AND FLUOROPYRIMIDINE VERSUS UPFRONT SURGERY FOR LOCALLY ADVANCED COLON CANCER: THE RANDOMIZED, PHASE III OPTICAL TRIAL.
